Diabetes study for patients with diabetes and renal impairment who are currently using basal insulin with or without Metformin or SGLT2 inhibitors

This study aims to investigate the effectiveness and safety of retatrutide, a new diabetes medication) at doses of 4 mg, 9 mg, or 12 mg that will be taken as a weekly injection for about 1 year, compared to a placebo. A participant's change in HbA1c level will be primary outcome of interest. We are seeking participants with type 2 diabetes that has affected kidney function and are currently taking long-acting insulin with metformin and/or a SGLT2 inhibitor.